Reata Pharmaceuticals, Inc. (RETA) financial statements (2021 and earlier)

Company profile

Business Address 5320 LEGACY DRIVE
PLANO, TX 75024
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments66433813085
Cash and cash equivalents66433813085
Deferred costs  0 
Other undisclosed current assets5433
Total current assets:66934213387
Noncurrent Assets
Property, plant and equipment3111
Other noncurrent assets10121
Total noncurrent assets:13322
TOTAL ASSETS:68234513589
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities26201510
Accounts payable2424
Accrued liabilities2415136
Deferred revenue5
Debt3 1 
Deferred revenue and credits2847
Contract with customer, liability31
Other liabilities12543
Other undisclosed current liabilities147   
Total current liabilities:192564860
Noncurrent Liabilities
Long-term debt and lease obligation162   
Long-term debt, excluding current maturities155   
Operating lease, liability7
Liabilities, other than long-term debt12195216245
Deferred revenue and credits216244
Deferred revenue5
Contract with customer, liability194
Other liabilities7100
Other undisclosed noncurrent liabilities607918 
Total noncurrent liabilities:234274235245
Total liabilities:426330282304
Stockholders' equity
Stockholders' equity attributable to parent, including:25715(147)(215)
Additional paid in capital96743519074
Accumulated deficit(710)(420)(337)(289)
Stockholders' equity note, subscriptions receivable  (0)(0)
Other undisclosed stockholders' equity attributable to parent0000
Total stockholders' equity:25715(147)(215)
TOTAL LIABILITIES AND EQUITY:68234513589

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenue, net4850
Gross profit:27544850
Operating expenses(312)(130)(95)(57)
Operating loss:(285)(77)(47)(7)
Nonoperating income (expense)(5)(4)(1)0
Investment income, nonoperating6410
Interest and debt expense(11)(1)(1) 
Loss from continuing operations before equity method investments, income taxes:(301)(82)(49)(7)
Other undisclosed income from continuing operations before income taxes1111 
Loss from continuing operations before income taxes:(290)(81)(48)(7)
Income tax expense (benefit)(0)(0)(0)0
Net loss available to common stockholders, diluted:(290)(81)(48)(6)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(290)(81)(48)(6)
Comprehensive loss, net of tax, attributable to parent:(290)(81)(48)(6)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: